Erythropoietin prevents dementia in hemodialysis patients

A nationwide population-based study

Peir Haur Hung, Chih Ching Yeh, Fung Chang Sung, Chih Yen Hsiao, Chih Hsin Muo, Kuan Yu Hung, Kuen Jer Tsai

Research output: Contribution to journalArticle

Abstract

Erythropoietic medications such as including erythropoietin (EPO) are known to be neuroprotective and to correlate with improved cognitive functions. However, it is not known whether supplementation with EPO reduces the risk of dementia in end-stage renal disease (ESRD) patients receiving hemodialysis (HD). Here, we determined whether EPO levels correlate with the incidence of different dementia subtypes, including Alzheimer's disease (AD), vascular dementia (VaD), and unspecified dementia (UnD), and whether such associations vary with annual cumulatively defined daily doses (DDDs) of EPO for ESRD patients receiving HD. This retrospective study included data from 43,906 adult ESRD patients who received HD between 1999 and 2010. Using hazard ratios and Cox regression models, we found that patients receiving EPO had a 39% lower risk of general dementia than those in the non-EPO group. Similarly, the risks of VaD and UnD was lower for patients in the EPO cohort. The risk of dementia was further reduced in HD patients treated with EPO in combination with iron. Our results suggest that the use of EPO medications in HD patients is associated with a reduced risk of VaD and UnD, but not AD, regardless of whether EPO is used alone or in combination with iron.

Original languageEnglish
Pages (from-to)6941-6950
Number of pages10
JournalAging
Volume11
Issue number17
DOIs
Publication statusPublished - Sep 1 2019

Fingerprint

Erythropoietin
Dementia
Renal Dialysis
Population
Vascular Dementia
Chronic Kidney Failure
Alzheimer Disease
Iron
Proportional Hazards Models
Cognition
Retrospective Studies
Incidence

Keywords

  • Alzheimer's disease
  • End-stage renal disease
  • Erythropoietin
  • Hemodialysis

ASJC Scopus subject areas

  • Ageing
  • Cell Biology

Cite this

Hung, P. H., Yeh, C. C., Sung, F. C., Hsiao, C. Y., Muo, C. H., Hung, K. Y., & Tsai, K. J. (2019). Erythropoietin prevents dementia in hemodialysis patients: A nationwide population-based study. Aging, 11(17), 6941-6950. https://doi.org/10.18632/aging.102227

Erythropoietin prevents dementia in hemodialysis patients : A nationwide population-based study. / Hung, Peir Haur; Yeh, Chih Ching; Sung, Fung Chang; Hsiao, Chih Yen; Muo, Chih Hsin; Hung, Kuan Yu; Tsai, Kuen Jer.

In: Aging, Vol. 11, No. 17, 01.09.2019, p. 6941-6950.

Research output: Contribution to journalArticle

Hung, PH, Yeh, CC, Sung, FC, Hsiao, CY, Muo, CH, Hung, KY & Tsai, KJ 2019, 'Erythropoietin prevents dementia in hemodialysis patients: A nationwide population-based study', Aging, vol. 11, no. 17, pp. 6941-6950. https://doi.org/10.18632/aging.102227
Hung, Peir Haur ; Yeh, Chih Ching ; Sung, Fung Chang ; Hsiao, Chih Yen ; Muo, Chih Hsin ; Hung, Kuan Yu ; Tsai, Kuen Jer. / Erythropoietin prevents dementia in hemodialysis patients : A nationwide population-based study. In: Aging. 2019 ; Vol. 11, No. 17. pp. 6941-6950.
@article{1275b329b8094f5fbe9b984a3315ddd3,
title = "Erythropoietin prevents dementia in hemodialysis patients: A nationwide population-based study",
abstract = "Erythropoietic medications such as including erythropoietin (EPO) are known to be neuroprotective and to correlate with improved cognitive functions. However, it is not known whether supplementation with EPO reduces the risk of dementia in end-stage renal disease (ESRD) patients receiving hemodialysis (HD). Here, we determined whether EPO levels correlate with the incidence of different dementia subtypes, including Alzheimer's disease (AD), vascular dementia (VaD), and unspecified dementia (UnD), and whether such associations vary with annual cumulatively defined daily doses (DDDs) of EPO for ESRD patients receiving HD. This retrospective study included data from 43,906 adult ESRD patients who received HD between 1999 and 2010. Using hazard ratios and Cox regression models, we found that patients receiving EPO had a 39{\%} lower risk of general dementia than those in the non-EPO group. Similarly, the risks of VaD and UnD was lower for patients in the EPO cohort. The risk of dementia was further reduced in HD patients treated with EPO in combination with iron. Our results suggest that the use of EPO medications in HD patients is associated with a reduced risk of VaD and UnD, but not AD, regardless of whether EPO is used alone or in combination with iron.",
keywords = "Alzheimer's disease, End-stage renal disease, Erythropoietin, Hemodialysis",
author = "Hung, {Peir Haur} and Yeh, {Chih Ching} and Sung, {Fung Chang} and Hsiao, {Chih Yen} and Muo, {Chih Hsin} and Hung, {Kuan Yu} and Tsai, {Kuen Jer}",
year = "2019",
month = "9",
day = "1",
doi = "10.18632/aging.102227",
language = "English",
volume = "11",
pages = "6941--6950",
journal = "Aging",
issn = "0002-0966",
publisher = "US Administration on Aging",
number = "17",

}

TY - JOUR

T1 - Erythropoietin prevents dementia in hemodialysis patients

T2 - A nationwide population-based study

AU - Hung, Peir Haur

AU - Yeh, Chih Ching

AU - Sung, Fung Chang

AU - Hsiao, Chih Yen

AU - Muo, Chih Hsin

AU - Hung, Kuan Yu

AU - Tsai, Kuen Jer

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Erythropoietic medications such as including erythropoietin (EPO) are known to be neuroprotective and to correlate with improved cognitive functions. However, it is not known whether supplementation with EPO reduces the risk of dementia in end-stage renal disease (ESRD) patients receiving hemodialysis (HD). Here, we determined whether EPO levels correlate with the incidence of different dementia subtypes, including Alzheimer's disease (AD), vascular dementia (VaD), and unspecified dementia (UnD), and whether such associations vary with annual cumulatively defined daily doses (DDDs) of EPO for ESRD patients receiving HD. This retrospective study included data from 43,906 adult ESRD patients who received HD between 1999 and 2010. Using hazard ratios and Cox regression models, we found that patients receiving EPO had a 39% lower risk of general dementia than those in the non-EPO group. Similarly, the risks of VaD and UnD was lower for patients in the EPO cohort. The risk of dementia was further reduced in HD patients treated with EPO in combination with iron. Our results suggest that the use of EPO medications in HD patients is associated with a reduced risk of VaD and UnD, but not AD, regardless of whether EPO is used alone or in combination with iron.

AB - Erythropoietic medications such as including erythropoietin (EPO) are known to be neuroprotective and to correlate with improved cognitive functions. However, it is not known whether supplementation with EPO reduces the risk of dementia in end-stage renal disease (ESRD) patients receiving hemodialysis (HD). Here, we determined whether EPO levels correlate with the incidence of different dementia subtypes, including Alzheimer's disease (AD), vascular dementia (VaD), and unspecified dementia (UnD), and whether such associations vary with annual cumulatively defined daily doses (DDDs) of EPO for ESRD patients receiving HD. This retrospective study included data from 43,906 adult ESRD patients who received HD between 1999 and 2010. Using hazard ratios and Cox regression models, we found that patients receiving EPO had a 39% lower risk of general dementia than those in the non-EPO group. Similarly, the risks of VaD and UnD was lower for patients in the EPO cohort. The risk of dementia was further reduced in HD patients treated with EPO in combination with iron. Our results suggest that the use of EPO medications in HD patients is associated with a reduced risk of VaD and UnD, but not AD, regardless of whether EPO is used alone or in combination with iron.

KW - Alzheimer's disease

KW - End-stage renal disease

KW - Erythropoietin

KW - Hemodialysis

UR - http://www.scopus.com/inward/record.url?scp=85072322821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072322821&partnerID=8YFLogxK

U2 - 10.18632/aging.102227

DO - 10.18632/aging.102227

M3 - Article

VL - 11

SP - 6941

EP - 6950

JO - Aging

JF - Aging

SN - 0002-0966

IS - 17

ER -